Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06770023 · ClinicalTrials.gov registry record · Phase 1

Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension

A Phase 1 study of Pulmonary Hypertension and Lung Transplant, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 1
Development phase
4
Enrollment target
1
Study location

NCT06770023 is a Phase 1 study of Pulmonary Hypertension and Lung Transplant that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 4 participants, below the 614-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06770023, a Phase 1 study of Pulmonary Hypertension and Lung Transplant, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 1
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if transseptal extra-corporeal membrane oxygenation (ECMO) can bridge pulmonary hypertension- right heart failure (PH-RVF) patients to lung transplant safely.

Interventions

  • DEVICE Protek Solo Transseptal Cannula

Study Locations (1)

Florida

  • Mayo Clinic in Florida - Jacksonville

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2025-12-11
Est. Completion 2028-12
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06770023

The ClinicalTrials.gov registry entry for NCT06770023 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 614-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Protek Solo Transseptal Cannula is the first listed.

NCT06770023 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06770023 about?

NCT06770023 is a clinical study titled "Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension". The purpose of this study is to determine if transseptal extra-corporeal membrane oxygenation (ECMO) can bridge pulmonary hypertension- right heart failure (PH-RVF) patients to lung transplant safely.

What is the current status of trial NCT06770023?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2025-12-11. Estimated completion is 2028-12.

What conditions does trial NCT06770023 study?

This clinical trial studies the following conditions: Pulmonary Hypertension, Lung Transplant.

What interventions are being tested in trial NCT06770023?

The interventions under investigation include: Protek Solo Transseptal Cannula (DEVICE).

Who is sponsoring clinical trial NCT06770023?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06770023 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.